Hormone mix could cut breast cancer risk and treat symptoms of menopause

Oct 19, 2009

The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.

Women in menopause who have symptoms, but have not had a hysterectomy are currently treated with a combination of plus hormone therapy, but this treatment comes with side effects, including a higher risk of caused by the progestin.

To find a better way of administering hormone therapy without the breast cancer risk, Hugh S. Taylor, M.D., professor in the Department of Obstetrics, & Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs. The team then looked at various markers of cell growth, including proliferating cell nuclear antigen (PCNA), one of the best-characterized markers of cell growth. The team found that PCNA was increased when they stimulated cells with estrogen and decreased when they added a SERM, indicating that the SERM blocked cell growth.

Taylor said that breast and uterine cells won't be stimulated by the estrogen plus SERM combination, so women in menopause get the benefits of estrogen without the risk of progestin. Progestin is a double-edged sword, Taylor said. It poses a breast cancer risk, but if you use estrogen alone without progestin, there is a higher risk of uterine cancer. SERMs appear to be a good substitute for progestin.

"In our study, the right combination of estrogen and various SERMs was able to prevent the proliferation of breast and endometrial cells, said Taylor. "These preliminary findings could lead to a better way of administering to women in ."

These laboratory results are currently being tested in large-scale clinical trials.

Source: Yale University (news : web)

Explore further: Pepper and halt: Spicy chemical may inhibit gut tumors

add to favorites email to friend print save as pdf

Related Stories

Hormone therapy raises cancer risk

Jan 16, 2008

Menopausal women who take hormone combinations for their symptoms are more likely to get an uncommon type of breast cancer much earlier than experts believed.

Recommended for you

Pepper and halt: Spicy chemical may inhibit gut tumors

10 hours ago

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining ...

Expressive writing may help breast cancer survivors

11 hours ago

Writing down fears, emotions and the benefits of a cancer diagnosis may improve health outcomes for Asian-American breast cancer survivors, according to a study conducted by a researcher at the University of Houston (UH).

Taking the guesswork out of cancer therapy

17 hours ago

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test ...

Brain tumour cells found circulating in blood

18 hours ago

(Medical Xpress)—German scientists have discovered rogue brain tumour cells in patient blood samples, challenging the idea that this type of cancer doesn't generally spread beyond the brain.

International charge on new radiation treatment for cancer

19 hours ago

(Medical Xpress)—Imagine a targeted radiation therapy for cancer that could pinpoint and blast away tumors more effectively than traditional methods, with fewer side effects and less damage to surrounding tissues and organs.

User comments : 0